{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:24:32Z","timestamp":1793118272981,"version":"4.5.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Breast secretory carcinoma (BSC) is a rare low-grade malignancy that frequently exhibits the ETV6::NTRK3 fusion gene and rarely presents with distant metastasis. In this report, we describe a case of 72-year-old female diagnosed with BSC, who presented with pleura and mediastinal lymph node metastases 10 years after undergoing radical mastectomy and radiotherapy. The primary tumor was characterized by a microcystic and solid architecture, eosinophilic secretions, and vacuolated cytoplasm. Immunohistochemistry (IHC) confirmed positivity for S-100 and pan-TRK. A decade later, respiratory symptoms prompted a PET\/CT scan that detected metabolically active metastases in pleura and mediastinal lymph nodes. Pleura mass biopsy revealed the same morphology and IHC profile (S-100+\/pan-TRK+), confirming metastatic BSC. GATA3 and TRPS1 overlap with salivary gland tumors necessitates PET\/CT for distinguishing the origin. Pan-TRK IHC and NTKR3 gene break positive confirmed secretory carcinoma. Following distant metastasis, immunotherapy combined with chemotherapy was initiated. After two treatment cycles, the patient was evaluated as having stable disease after two treatment cycles, but disease progression occurred in the later four cycles. The treatment was changed to entrectinib targeted therapy, the PET\/CT re-examination showed partial remission. This case highlights the rare metastatic risk of BSC and the diagnostic necessity of integrating clinical, imaging, histopathology, and NTRK3 break-apart probe detection. Targeted therapies including NTRK3 inhibitors, show promise emphasizing the importance of multidisciplinary management for this malignancy. Awareness of BSC\u2019s metastatic potential and tailored therapeutic strategies are crucial for optimizing outcomes.<\/jats:p>","DOI":"10.3389\/fonc.2025.1641375","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:27:50Z","timestamp":1758605270000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Metastasis to pleura and mediastinal lymph nodes from breast secretory carcinoma: 10 years follow-up"],"prefix":"10.3389","volume":"15","author":[{"given":"Fengbo","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglian","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuming","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"B1","volume-title":"WHO classification of tumours of the breast","year":"2019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"14738","DOI":"10.1038\/s41598-021-94351-w","article-title":"Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast","volume":"11","author":"Gong","year":"2021","journal-title":"Sci Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13000-021-01156-6","article-title":"Secretory breast carcinoma in a female adult with liver metastsis: a case report and literature review","volume":"16","author":"Lian","year":"2021","journal-title":"Diagn Pathol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13000-021-01115-1","article-title":"Secretory carcinoma of the breast with multiple distant metastases in the brain and unfavorable prognosis: a case report and literature review","volume":"16","author":"Tang","year":"2021","journal-title":"Diagn Pathol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/tbcr-24-31","article-title":"Chinese society of clinical oncology (CSCO) breast cancer guidelines 2024","volume":"5","author":"Li","year":"2024","journal-title":"Transl Breast Cancer Res"},{"key":"B6","article-title":"Juvenile secretory carcinoma and juvenile papillomatosis","volume":"15","author":"Tokunaga","year":"1985","journal-title":"Jpn J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/dc.24945","article-title":"Cytological and molecular characterization of secretory breast carcinoma","volume":"50","author":"Carretero-Barrio","year":"2022","journal-title":"Diagn Cytopathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.190","article-title":"Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature","volume":"25","author":"Li","year":"2012","journal-title":"Mod Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.32","article-title":"Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas","volume":"30","author":"Krings","year":"2017","journal-title":"Mod Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/his.13232","article-title":"Secretory breast carcinoma with a papillary-predominant pattern: an unusual morphological variant","volume":"71","author":"Shui","year":"2017","journal-title":"Histopathology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07153-1","article-title":"Secretory breast carcinoma: clinicopathological features and prognosis of 52 patients","volume":"203","author":"Zhao","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2024.01.004","article-title":"A Comparative Evaluation of TRPS1 and GATA3 in adenoid cystic, secretory, and acinic cell carcinomas of the breast and salivary gland","volume":"145","author":"Salem","year":"2024","journal-title":"Hum Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001366","article-title":"Pan-TRK immunohistochemistry: A useful diagnostic adjunct for secretory carcinoma of the breast","volume":"43","author":"Harrison","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jcp-2023-208989","article-title":"Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma","volume":"77","author":"Ye","year":"2024","journal-title":"J Clin Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07583-5","article-title":"Secretory breast carcinoma: a multicenter clinicopathologic study of 80 cases with emphasis on prognostic analysis and chemotherapy benefit","volume":"210","author":"Qi","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02677-x","article-title":"Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2174\/0929867328666210914121324","article-title":"Entrectinib: A new selective tyrosine kinase inhibitor approved for the treatment of pediatric and adult patients with NTRK fusionpositive, recurrent or advanced solid tumors","volume":"29","author":"Osman","year":"2022","journal-title":"Curr Med Chem"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1641375\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:28:01Z","timestamp":1758605281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1641375\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":17,"alternative-id":["10.3389\/fonc.2025.1641375"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1641375","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"article-number":"1641375"}}